Indication Matters: Study Shows Trial Characteristics Of Approved Drugs Vary Widely Across Diseases
Executive Summary
FDA data requirements supporting novel drug approvals vary widely, depending on therapeutic area, with cancer drugs given greatest leniency, suggesting products may need a clinical trial “quality grade,” according to an analysis published in the Journal of the American Medical Association. Another study shows cancer treatments are most likely to get approved on the first try.